Last reviewed 2026-04-23 · How we verify

Omnic Ocas

Omnic Ocas is a once-daily oral formulation of tamsulosin that selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck to relieve urinary obstruction.

Omnic Ocas is a once-daily oral formulation of tamsulosin that selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck to relieve urinary obstruction. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.

At a glance

Mechanism of action

Tamsulosin is an alpha-1A selective antagonist that reduces smooth muscle tone in the prostate and bladder outlet, improving urine flow and reducing lower urinary tract symptoms. The Ocas (oral controlled absorption system) formulation provides sustained release of the active ingredient, allowing for once-daily dosing with improved tolerability compared to immediate-release formulations.

Approved indications

• Benign prostatic hyperplasia with lower urinary tract symptoms

Common side effects

• Retrograde ejaculation
• Dizziness
• Headache
• Asthenia/fatigue
• Orthostatic hypotension

Key clinical trials

• Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia (PHASE3)
• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions (PHASE1)
• A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State (PHASE1)
• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions (PHASE1)
• Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
• EC905 Pharmacokinetic Profile Study (PHASE1)
• Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction (PHASE2)
• A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.